Developer docs
API playgroundTry for free, no card

Search company profiles

Gubra

Full company profile

uuid00056p6

Namestring
Gubra
Legal namestring
Gubra A/S
Websiteurl
gubra.dk
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Gubra A/S is a Danish publicly-listed biotech company (Nasdaq Copenhagen, IPO March 2023 at DKK 110/share) operating a hybrid model that combines proprietary peptide drug discovery and development with a contract research organization (CRO) services business. Headquartered in Hørsholm, Denmark, with additional offices in Cambridge, Massachusetts and Allschwil, Switzerland, the company employs approximately 300 people as of early 2026 and serves pharmaceutical and biotechnology clients globally, with documented relationships with 17 of the 20 largest pharmaceutical companies worldwide.

Gubra's core technology is the streaMLine platform, an AI/ML-driven peptide drug discovery system integrating machine learning with high-throughput peptide synthesis (over 4,000 peptides per month) to compress screening-to-candidate selection timelines to 12-15 months. Complementing this are specialized preclinical capabilities including fully automated 3D light-sheet fluorescence microscopy accommodating up to 100 brains per study, AI-driven image analysis, and proprietary disease models such as the GAN DIO-MASH mouse model ranked #1 for human translatability by the LITMUS consortium. The pipeline includes the wholly-owned GUB-UCN2 urocortin-2 analog for muscle-preserving obesity treatment (CTA filed in Germany), and partnered programs including ABBV-295 (amylin analog licensed to AbbVie, Phase 1 showed 7.75-9.79% body weight loss), BI 3034701 (triple GLP-1/GIP/NPY2 agonist with Boehringer Ingelheim, Phase 2 mid-2026), AMX0318 (GLP-1R antagonist with Amylyx, IND targeted 2027), and a PTH analog (with Camurus for hypoparathyroidism).

Revenue is generated through two primary streams: CRO preclinical services sold via direct B2B engagement with pharma/biotech R&D decision-makers, and outlicensing of drug candidates for upfront payments, development and commercial milestones, and tiered royalties. The AbbVie deal for ABBV-295 — $350M upfront with up to $1.875B in milestones plus royalties — exemplifies the licensing economics. FY2025 revenue reached DKK 2,637 million (~$390M USD), with record Q4 2025 net profit of DKK 1,700M driven primarily by the AbbVie upfront. In February 2026, Gubra launched a third business unit, Gubra Ventures, to incubate new biotech companies from internal research, alongside its existing Biotech and CRO units.

Short descriptiontext

Gubra A/S is a Danish publicly-listed biotech combining AI-driven peptide drug discovery (via its streaMLine platform) with preclinical CRO services, serving 17 of the 20 largest global pharmaceutical companies through proprietary disease models and partnered development programs in obesity and metabolic disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersHørsholm, Denmark
HQ citystring
Hørsholm
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peptide drug discovery, preclinical CRO services, metabolic disease research, obesity therapeutics, AI drug discovery
Industry1 code
PRIMARYHLAKADAA
Diabetes (General)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Preclinical Drug Discovery and Contract Research Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Revenue from outlicensing drug candidates to pharmaceutical partners. Gubra receives upfront payments, development milestones, commercial milestones, and royalties on net sales. The landmark AbbVie deal for ABBV-295 included $350M upfront and up to $1.875B in milestones plus royalties.

in.investing.com
2CRO Services (Contract Research Organization)
TypeProfessional Services
Description

Preclinical contract research services provided to pharmaceutical and biotech companies across multiple therapeutic areas including liver, obesity, kidney, CNS, lung, diabetes, women's health, and muscle research. Services include 3D imaging, histology, RNA sequencing, and non-rodent studies.

gubra.dk
3Milestone Payments from Collaborations
TypeLicensing Royalties
Description

Payments received upon achievement of development milestones. For example, $4m milestone payment from Amylyx for selection of AMX0318 as development candidate, with potential milestones exceeding $50m plus royalties.

simplywall.st
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Gubra Green
Description

Gubra's dedicated business unit for investing 10% of annual pre-tax profits in initiatives supporting greenhouse gas emissions reduction and biodiversity restoration.

gubra.dk
Core offering1 text field

Gubra is an integrated biotech company that discovers and develops peptide-based therapeutics (with a focus on obesity and metabolic diseases) and provides preclinical contract research services to pharmaceutical and biotech companies. The company operates three business units: Gubra Biotech (internal drug discovery), Gubra CRO Services (preclinical contract research), and Gubra Ventures (incubator for new biotech companies). Service offerings span in vivo pharmacology, 3D imaging, and translational research, supported by the proprietary streaMLine AI platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • ABBV-295 achieved 7.75% to 9.79% body weight loss in Phase 1 trial after ~3 months
+3 more records
Product overview1 text field

Gubra operates as an integrated biotech company organized into three synergistic business units: Biotech, CRO Services, and Ventures. The Biotech unit advances proprietary peptide drug candidates including GUB-UCN2 for obesity (muscle-preserving weight loss) and manages partnered programs including ABBV-295 (amylin analog, licensed to AbbVie), BI 3034701 (triple agonist, Boehringer Ingelheim), AMX0318 (Amylyx), and PTH analog (Camurus). The CRO Services unit provides preclinical contract research across liver, obesity, kidney, CNS, lung, diabetes, women's health, and muscle areas, supported by specialized technologies including 3D imaging, histology, and RNASeq. The Ventures unit creates new biotech companies from Gubra's research. Core technology includes the streaMLine AI-driven peptide discovery platform and GubraView data visualization tool. The company also operates Gubra Green, a sustainability subsidiary committing 10% of pre-tax profits to environmental initiatives.

Product and service3 records
1Gubra CRO Services
CategoryContract Research Organization (CRO) services
Description

Preclinical contract research organization offering in vivo pharmacology, in vitro assays, 3D imaging, and translational studies to biotech and pharmaceutical clients, with deep specialization in metabolic, obesity, gastrointestinal, and CNS disease models.

2Gubra Biotech (Internal Drug Discovery & Licensing)
CategoryDrug discovery and licensing
Description

Proprietary peptide-based drug discovery and development unit focused on obesity, metabolic disease, and related indications. Generates licensable drug candidates (e.g., GUB-UCN2, AMX0318, PTH Analog, ABBV-295, BI 3034701) for pharmaceutical partners.

3Gubra Ventures
CategoryBiotech incubation and venture creation
Description

Biotech incubator and venture creation unit that builds and launches new companies based on Gubra's research capabilities and discoveries.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Collaboration to develop long-acting treatment for hypoparathyroidism combining Gubra's PTH analogue with Camurus' FluidCrystal technology to enable extended, patient-friendly dosing.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-03-01
Description

License agreement for GUB014295 (ABBV-295), Gubra's long-acting amylin analog for obesity treatment. AbbVie received global rights to develop and commercialize. Gubra receives $350M upfront and up to $1.875B in development, commercial and sales milestones plus tiered royalties. Phase 1 trials showed 7.75-9.79% body weight loss.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-30
Description

Research collaboration to develop AMX0318, a novel long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases. $4M milestone paid for development candidate selection; potential milestones exceeding $50M plus royalties. IND targeted for 2027.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-11-15
Description

Collaboration on inflammatory bowel disease (IBD) research.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-09-20
Description

Collaboration to develop next generation cardiorenal treatments. (Collaboration subsequently terminated per 2023 announcement)

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-06-18
Description

Collaboration to develop a new glucose responsive insulin for diabetes.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2013-09-23
Description

Research collaboration to discover and develop peptide-based drugs targeting diabetes and obesity. Gubra reached third research milestone under this agreement.

8Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multiple obesity partnerships: BI 3034701 (triple GLP-1/GIP/NPY2 agonist) advanced to Phase 2 in 2026; BI 1820237 (NPY2R agonist) discontinued for obesity but opportunities outside obesity being explored. Boehringer responsible for global clinical development and commercialization.

gubra.dk
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration for PTH analog development for bleeding disorder treatment.

Strategic tierMinorTypeOthers
Description

Landlord and facility provider for Gubra's expanded laboratory and office space at DTU Science Park in Hørsholm, Denmark. 70% space expansion to nearly 10,000 m².

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

AI-driven drug discovery platform combining high-throughput biology with machine learning. Partial overlap with Gubra's streaMLine platform thesis, though focused on small molecules and rare diseases.

TypeDirect peer
Description

Danish peptide therapeutics company developing its own metabolic/obesity pipeline and partnering with larger pharma. Closest geographic and mechanistic peer to Gubra, with similar hybrid platform-and-pipeline orientation.

3PeptiDream
TypeDirect peer
Description

Japan-based peptide discovery platform company using proprietary technology to generate therapeutic peptides for pharma partners. Highly comparable to Gubra's streaMLine platform and outlicensing model.

TypeDirect peer
Description

AI/ML-driven drug discovery platform with co-development and licensing revenue streams. Comparable to Gubra's streaMLine platform positioning, although Schrödinger operates more broadly across small molecules and biologics.

TypeBroad incumbent
Description

Danish global leader in diabetes and obesity therapeutics (GLP-1 class originator). Not a direct competitor in discovery but the dominant force in the metabolic disease indications Gubra's pipeline targets.

TypeBroad incumbent
Description

Global pharmaceutical leader with dominant position in obesity (Mounjaro/Zepbound). Operates at the commercialization end of the value chain that Gubra's partnered assets flow into.

TypeBroad incumbent
Description

Largest preclinical CRO with broad service offerings including discovery and safety assessment. Comparable Gubra's CRO Services business unit, though at vastly greater scale.

8Labcorp
TypeBroad incumbent
Description

Diversified CRO with early development services comparable to Gubra's preclinical CRO offerings. Operates at much larger scale across multiple therapeutic areas.

TypeEmerging player
Description

Clinical-stage metabolic disease biotech focused on obesity and related conditions. Comparable emerging-player peer overlapping Gubra's metabolic/obesity pipeline focus.

TypeEmerging player
Description

Preclinical CRO specializing in oncology and metabolic disease models, including MASH/NASH capabilities. Closest mid-sized CRO peer to Gubra's specialized preclinical service portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Gubra

Preclinical Drug Discovery and Contract Research Servicesgubra.dk

Gubra A/S is a Danish publicly-listed biotech combining AI-driven peptide drug discovery (via its streaMLine platform) with preclinical CRO services, serving 17 of the 20 largest global pharmaceutical companies through proprietary disease models and partnered development programs in obesity and metabolic disease.

What Gubra does

Gubra A/S is a Danish publicly-listed biotech company (Nasdaq Copenhagen, IPO March 2023 at DKK 110/share) operating a hybrid model that combines proprietary peptide drug discovery and development with a contract research organization (CRO) services business. Headquartered in Hørsholm, Denmark, with additional offices in Cambridge, Massachusetts and Allschwil, Switzerland, the company employs approximately 300 people as of early 2026 and serves pharmaceutical and biotechnology clients globally, with documented relationships with 17 of the 20 largest pharmaceutical companies worldwide.

Gubra's core technology is the streaMLine platform, an AI/ML-driven peptide drug discovery system integrating machine learning with high-throughput peptide synthesis (over 4,000 peptides per month) to compress screening-to-candidate selection timelines to 12-15 months. Complementing this are specialized preclinical capabilities including fully automated 3D light-sheet fluorescence microscopy accommodating up to 100 brains per study, AI-driven image analysis, and proprietary disease models such as the GAN DIO-MASH mouse model ranked #1 for human translatability by the LITMUS consortium. The pipeline includes the wholly-owned GUB-UCN2 urocortin-2 analog for muscle-preserving obesity treatment (CTA filed in Germany), and partnered programs including ABBV-295 (amylin analog licensed to AbbVie, Phase 1 showed 7.75-9.79% body weight loss), BI 3034701 (triple GLP-1/GIP/NPY2 agonist with Boehringer Ingelheim, Phase 2 mid-2026), AMX0318 (GLP-1R antagonist with Amylyx, IND targeted 2027), and a PTH analog (with Camurus for hypoparathyroidism).

Revenue is generated through two primary streams: CRO preclinical services sold via direct B2B engagement with pharma/biotech R&D decision-makers, and outlicensing of drug candidates for upfront payments, development and commercial milestones, and tiered royalties. The AbbVie deal for ABBV-295 — $350M upfront with up to $1.875B in milestones plus royalties — exemplifies the licensing economics. FY2025 revenue reached DKK 2,637 million (~$390M USD), with record Q4 2025 net profit of DKK 1,700M driven primarily by the AbbVie upfront. In February 2026, Gubra launched a third business unit, Gubra Ventures, to incubate new biotech companies from internal research, alongside its existing Biotech and CRO units.

Gubra firmographics

Firmographics
Name
Gubra
Legal name
Gubra A/S
Website
https://gubra.dk
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
251–500 employees
Short description
Gubra A/S is a Danish publicly-listed biotech combining AI-driven peptide drug discovery (via its streaMLine platform) with preclinical CRO services, serving 17 of the 20 largest global pharmaceutical companies through proprietary disease models and partnered development programs in obesity and metabolic disease.
Ownership category
akta.pro rank

Gubra industry classification

Industry
Product category
Preclinical Drug Discovery and Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAKADAA
Diabetes (General)

Keywords

  • Peptide drug discovery
  • Preclinical CRO services
  • Metabolic disease research
  • Obesity therapeutics
  • AI drug discovery

Where Gubra is headquartered

Location

Headquarters

HQ city
Hørsholm
HQ country
Denmark
HQ region
Europe

Offices3 records

Markets served

Gubra business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and Milestone Payments: Revenue from outlicensing drug candidates to pharmaceutical partners. Gubra receives upfront payments, development milestones, commercial milestones, and royalties on net sales. The landmark AbbVie deal for ABBV-295 included $350M upfront and up to $1.875B in milestones plus royalties.
  2. CRO Services (Contract Research Organization): Preclinical contract research services provided to pharmaceutical and biotech companies across multiple therapeutic areas including liver, obesity, kidney, CNS, lung, diabetes, women's health, and muscle research. Services include 3D imaging, histology, RNA sequencing, and non-rodent studies.
  3. Milestone Payments from Collaborations: Payments received upon achievement of development milestones. For example, $4m milestone payment from Amylyx for selection of AMX0318 as development candidate, with potential milestones exceeding $50m plus royalties.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Gubra product offering

Product offering

Core offering

Gubra is an integrated biotech company that discovers and develops peptide-based therapeutics (with a focus on obesity and metabolic diseases) and provides preclinical contract research services to pharmaceutical and biotech companies. The company operates three business units: Gubra Biotech (internal drug discovery), Gubra CRO Services (preclinical contract research), and Gubra Ventures (incubator for new biotech companies). Service offerings span in vivo pharmacology, 3D imaging, and translational research, supported by the proprietary streaMLine AI platform.

Product overview

Gubra operates as an integrated biotech company organized into three synergistic business units: Biotech, CRO Services, and Ventures. The Biotech unit advances proprietary peptide drug candidates including GUB-UCN2 for obesity (muscle-preserving weight loss) and manages partnered programs including ABBV-295 (amylin analog, licensed to AbbVie), BI 3034701 (triple agonist, Boehringer Ingelheim), AMX0318 (Amylyx), and PTH analog (Camurus). The CRO Services unit provides preclinical contract research across liver, obesity, kidney, CNS, lung, diabetes, women's health, and muscle areas, supported by specialized technologies including 3D imaging, histology, and RNASeq. The Ventures unit creates new biotech companies from Gubra's research. Core technology includes the streaMLine AI-driven peptide discovery platform and GubraView data visualization tool. The company also operates Gubra Green, a sustainability subsidiary committing 10% of pre-tax profits to environmental initiatives.

Differentiator

Problem solved

Functional benefit

Brands

  • Gubra Green: Gubra's dedicated business unit for investing 10% of annual pre-tax profits in initiatives supporting greenhouse gas emissions reduction and biodiversity restoration.

Products and services

  • Gubra CRO Services Preclinical contract research organization offering in vivo pharmacology, in vitro assays, 3D imaging, and translational studies to biotech and pharmaceutical clients, with deep specialization in metabolic, obesity, gastrointestinal, and CNS disease models.
  • Gubra Biotech (Internal Drug Discovery & Licensing) Proprietary peptide-based drug discovery and development unit focused on obesity, metabolic disease, and related indications. Generates licensable drug candidates (e.g., GUB-UCN2, AMX0318, PTH Analog, ABBV-295, BI 3034701) for pharmaceutical partners.
  • Gubra Ventures Biotech incubator and venture creation unit that builds and launches new companies based on Gubra's research capabilities and discoveries.

Quantifiable outcome

  • ABBV-295 achieved 7.75% to 9.79% body weight loss in Phase 1 trial after ~3 months
  • +3 more outcomes

Companies that use Gubra

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Gubra technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Gubra partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, flagship and minor.

  • CamuruscoreStrategic or Co-development Partner · 1 December 2025Collaboration to develop long-acting treatment for hypoparathyroidism combining Gubra's PTH analogue with Camurus' FluidCrystal technology to enable extended, patient-friendly dosing.
  • AbbVieflagshipStrategic or Co-development Partner · 1 March 2025License agreement for GUB014295 (ABBV-295), Gubra's long-acting amylin analog for obesity treatment. AbbVie received global rights to develop and commercialize. Gubra receives $350M upfront and up to $1.875B in development, commercial and sales milestones plus tiered royalties. Phase 1 trials showed 7.75-9.79% body weight loss.
  • Amylyx PharmaceuticalscoreStrategic or Co-development Partner · 30 December 2024Research collaboration to develop AMX0318, a novel long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases. $4M milestone paid for development candidate selection; potential milestones exceeding $50M plus royalties. IND targeted for 2027.
  • FerringminorStrategic or Co-development Partner · 15 November 2022Collaboration on inflammatory bowel disease (IBD) research.
  • BayerminorStrategic or Co-development Partner · 20 September 2021Collaboration to develop next generation cardiorenal treatments. (Collaboration subsequently terminated per 2023 announcement)
  • JDRFminorStrategic or Co-development Partner · 18 June 2018Collaboration to develop a new glucose responsive insulin for diabetes.
  • SanofiminorStrategic or Co-development Partner · 23 September 2013Research collaboration to discover and develop peptide-based drugs targeting diabetes and obesity. Gubra reached third research milestone under this agreement.
  • Boehringer IngelheimcoreStrategic or Co-development PartnerMultiple obesity partnerships: BI 3034701 (triple GLP-1/GIP/NPY2 agonist) advanced to Phase 2 in 2026; BI 1820237 (NPY2R agonist) discontinued for obesity but opportunities outside obesity being explored. Boehringer responsible for global clinical development and commercialization.
  • HemabminorStrategic or Co-development PartnerCollaboration for PTH analog development for bleeding disorder treatment.
  • DTU Science ParkminorOthersLandlord and facility provider for Gubra's expanded laboratory and office space at DTU Science Park in Hørsholm, Denmark. 70% space expansion to nearly 10,000 m².

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Gubra competitors and assessment

Company assessment

Emerging players

  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning. Partial overlap with Gubra's streaMLine platform thesis, though focused on small molecules and rare diseases.
  • BioAge Labs: Clinical-stage metabolic disease biotech focused on obesity and related conditions. Comparable emerging-player peer overlapping Gubra's metabolic/obesity pipeline focus.
  • Crown Bioscience: Preclinical CRO specializing in oncology and metabolic disease models, including MASH/NASH capabilities. Closest mid-sized CRO peer to Gubra's specialized preclinical service portfolio.

Direct peers

  • Zealand Pharma: Danish peptide therapeutics company developing its own metabolic/obesity pipeline and partnering with larger pharma. Closest geographic and mechanistic peer to Gubra, with similar hybrid platform-and-pipeline orientation.
  • PeptiDream: Japan-based peptide discovery platform company using proprietary technology to generate therapeutic peptides for pharma partners. Highly comparable to Gubra's streaMLine platform and outlicensing model.
  • Schrödinger: AI/ML-driven drug discovery platform with co-development and licensing revenue streams. Comparable to Gubra's streaMLine platform positioning, although Schrödinger operates more broadly across small molecules and biologics.

Broad incumbents

  • Novo Nordisk: Danish global leader in diabetes and obesity therapeutics (GLP-1 class originator). Not a direct competitor in discovery but the dominant force in the metabolic disease indications Gubra's pipeline targets.
  • Eli Lilly: Global pharmaceutical leader with dominant position in obesity (Mounjaro/Zepbound). Operates at the commercialization end of the value chain that Gubra's partnered assets flow into.
  • Charles River Laboratories: Largest preclinical CRO with broad service offerings including discovery and safety assessment. Comparable Gubra's CRO Services business unit, though at vastly greater scale.
  • Labcorp: Diversified CRO with early development services comparable to Gubra's preclinical CRO offerings. Operates at much larger scale across multiple therapeutic areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Gubra social profiles

Digital presence

Gubra financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Gubra leadership team

Management profile

Number of profiles

Profiles12 records

Gubra subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Gubra funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Gubra M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gubra

What does Gubra do?

Gubra is an integrated biotech company that discovers and develops peptide-based therapeutics (with a focus on obesity and metabolic diseases) and provides preclinical contract research services to pharmaceutical and biotech companies. The company operates three business units: Gubra Biotech (internal drug discovery), Gubra CRO Services (preclinical contract research), and Gubra Ventures (incubator for new biotech companies). Service offerings span in vivo pharmacology, 3D imaging, and translational research, supported by the proprietary streaMLine AI platform.

Is Gubra a public or private company?

Gubra is a public company. It is classified as public and is currently operating.

When was Gubra founded?

Gubra was founded in 2015. It employs 251 to 500 people.

Where is Gubra based?

Gubra is headquartered in Hørsholm, Denmark, in the Europe region.

How does Gubra make money?

Three revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are CRO Services (Contract Research Organization) and milestone Payments from Collaborations.

Who are Gubra's main competitors?

Emerging players on record are Recursion Pharmaceuticals, BioAge Labs and Crown Bioscience. Direct peers are Zealand Pharma, PeptiDream and Schrödinger. Broad incumbents are Novo Nordisk, Eli Lilly, Charles River Laboratories and Labcorp.

Does Gubra have an API?

No public API is recorded for Gubra.

What industry is Gubra in?

Gubra's product category is Preclinical Drug Discovery and Contract Research Services. Its primary akta.pro industry code is HLAKADAA, Diabetes (General). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewGubra to participate in upcoming investor conferencesGubra announced that its leadership team will attend the Jefferies 2026 Global Healthcare Conference in London on November 16-19, 2026, and the ABG Sundal Collier Nordic Opportunities Seminar on November 17-19, 2026. The company, a clinical-stage bioscience firm, reported revenue of DKK 2.6 billion in 2025.Investing.comAmylyx at Stifel 2026 healthcare conference: avexitide nears launchAmylyx Pharmaceuticals reported at the Stifel 2026 Healthcare Conference that its Phase 3 trial for avexitide met its primary endpoint with a P-value of 0.000003, supporting an NDA filing before year-end 2024. The company estimates 160,000 U.S. patients have post-bariatric hypoglycemia and targets a 2027 commercial launch. It is also developing a long-acting injectable with Gubra, expecting an NDA in 2025.Dagens industriDanska Gubras vd lämnar omedelbartGubras CEO Markus Rohrwild is leaving the position immediately. The announcement is a paywall stub with no further details.BorsenGubra fyrer topchef – vil køre med to chefer frem mod 2030Gubra, a biotech company, is moving from one top chef to two, with no reason given. The two new chefs are not a temporary solution, according to the company.Seeking AlphaGubra A/S (GUBRF) Q3 2026 Sales/Trading Call TranscriptGubra reported strong Q3 2026 results, with its CRO business growing 6% year-on-year and EBIT margin improving to 25%. The company advanced two obesity programs to Phase II and entered Phase I clinical development for its GUB-UCN2 analog.BorsenGubra-topchef: Så længe vi vokser, vil overskuds­graden være godGubra's top chef Markus Rohrwild said the company's profitability can remain high in coming years. Two milestone payments of 400 million kr. came from partners advancing two weight-loss drugs, while the CRO unit grew revenue by 6% and posted a 25% profit margin.TradingViewGubra Q3 2026 Earnings Call Is LiveGubra's Q3 2026 earnings call is live, with executives discussing financial results and answering analyst questions. Management commentary on demand, margins, or capital spending may move markets.BorsenGubra firedobler omsætning: Justerer målGubra cut its 2026 revenue expectations after Q3 2025 revenue more than quadrupled to 447.7M kr, up from 99.1M kr in Q3 2025. The increase was driven by milestone payments from AbbVie and Boehringer Ingelheim after two weight-loss drug programs advanced to Phase 2.Seeking AlphaGubra A/S (GUBRF) Shareholder/Analyst Call TranscriptGubra A/S held its first shareholder/analyst call on October 27, 2026, with CEO Markus Rohrwild and others presenting the company's 2030 strategy. The call included forward-looking statements about the company's ambitions and pipeline.BorsenGubra-topchef med ny strategi: Satser på 10 væksthåb frem mod 2030Gubra, a biotech firm from Hørsholm, will accelerate its research and development to increase the number of drug candidates in its pipeline. The company, which was contract research-focused before its 2023 IPO, now aims to develop its own drug candidates, targeting up to 10 growth candidates by 2030.